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Summary: We evaluated the levels of CA 19-9 and CA 125 in the sera of healthy individuals, patients with non-
neoplastic diseases known to produce elevated serum concentrations of CA 19-9 and CA 125, and patients with
malignant tumours. The serum concentrations determined with an immunoradiometric assay (IRMA) and an
immunoluminometric assay (ILMA) were compared. The accuracy was determined (äs far äs this is possible in the
absence of reference method values), äs well äs the precision (intra-assay Variation and inter-assay Variation), using
internal and external controls.
The serum concentrations were comparable in both test Systems (coefficient of correlation, KendalPs Tau of CA 19-
9: 0.88, p < 0.001; CA 125: 0.87, p < 0.001). The linearity of both assays was excellent when serum samples were
diluted (r > 0.98 in all assays tested). The intra-assay Variation of CA 19-9 IRMA was less than that of CA 19-9
ILMA, and was comparable for CA 125 in both assays. The coefficients of Variation of duplicates were nearly
independent of the antigen concentration within the ränge 20-1000kU/l (mean CV CA 19-9: 3.7% and 3.9% for
IRMA and ILMA, respectively; mean CV CA 125: 3.9% and 5.6% for IRMA and ILMA, respectively). In the
assay of external controls, the performance of the IRMAs was foiind to be slightly better than that of the ILMAs,
but it was not satisfactory. We conclude that, with some improvements in quality control, luminescence assays are
a possible alternative to isotopic assays in the clinical laboratory.
Introduction and follow-up after surgical Intervention, in order to de-
tect a possible recurrence of a tumour (4—9).
The labelling of antibodies in immunological assays
with chemiluminescent molecules is another step We evaluated the levels ofCA 19-9 and CA 125 in the
towards a routine laboratory free of radioisotopes (l, 2). sera of a selected collective, comprising healthy individ-
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aminobutylethylispluminol (6-[N-(4-aminobutyl)-N^ Produce elevated serum concentrations of CA 19-9 and
ethyl] aminophthalazine 1,4 (2H,3H) dione) to the re- CA 125 (10~12)' and Patients with maliSnant tumours·
spective carboxylic acid in alkaline solution, with the The ^ncentrations determined with an immunoradio-
r·,· u* . , ., r>tor /o\ A i· rnetric assay and an immunoluminometric assay were
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tution of new test methods for those akeady established
are similar accuracy and precision. The concordanee of
the serum concenträtions is particularly important, since Materials and Methods
tumour markers are generally interpreted over long per-
 We used the commercially available assays CA 19-9 RIA and CA
iods of time, e. g. response during cancer chemotherapy 125 RIA from Centocor (Malvern, Pennsylvania, USA) and LIA-
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Tab. l Test proccdurc for the evaluation of CA 19-9 and CA 125. Results
IRMA ILMA
Evaluation of CA 19-9
Buffer
Serum sample
First incubation
Washing step
Addition of tracer
Second incubation at
room temperature
Washing step and measuring
procedure
Upper limit of the assay:
0.1 ml
O. lml
3 hat
37 °C
0.2ml
3h
240 kU/l
0.2ml
O . l m l
in a
water-bath
0.3ml
18-20 h
120kU/l
Evaluation of CA 125
Serum sample 0.1 ml 0.1 ml
Addition of tracer 0. l ml 0.2 ml
Incubation at room temperature 20 h 20 h
on an orbital shaker
Washing step and measuring
procedure
Upper limit of the assay: 500 kU/l 400 kU/l
Concordance of CA 19-9 and
CA 125 concentrations in serum
With some exceptions, the concentrations of CA 19-9
(fig. 1) and CA 125 (fig. 2) in serum were comparable
in both test Systems (coefficient of correlatiön, KendaWs
Tau, CA 19-9: 0.88, p<0.0<31; CA 125: 0.87,
p < 0.001).
The following equations can be used for the conversion
of the test results from one assay to the other:
CA 19-9: value ILMA = 1.005 X value IRMA + 9.0
(Standard error of the slope: 0.010, intercept: 8.6;
n = 184)
CA 125: value ILMA = 0.999 X value IRMA - 5.5
(Standard error of the slope: 0.007, intercept: 8.0;
n = 188)
mat 19-9 and LIA-mat 125 from Byk-Sangrec Diagnostica (Diet-
zenbach, Germany) under the conditions listed in table 1.
The activity of I25I was measured on a gamma-counter (model
Crystal II, Packard, Illinois, USA). The Standard curve of CA 19-9
IRMA was fitted to a cubic spline function (mass action smooth
splining), and linear fitting was used for CA 125 IRMA. Chemi-
luminescence was measured using a CliniLumat (Berthold, Wild-
bad, Germany). The light signal was integrated over the 5 second
interval immediately following the injection of 0.3 ml alkaline per-
oxide solution and 0.3 ml catalyst solution. The Standard curves in
both LIA-mat assays were adjusted with a quadratic spline ftinction
after a log/logit transformation of the signal.
Each sample was performed in duplicate and the evaluation of
serum specimens was repeated if the coeflBcient of Variation ex-
ceeded 10%. Six specimens were used for quality control, three
external (Bioref, Mömbris, Germany and Lyphocheck level l and
2, Biorad Laboratories, Hercules CA), and three internal controls
(one ILMA kit control and two IRMA kit controls).
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Fig. l Correlatiön of CA 19-9 vaiues for 184 serum samples.
Dotted lines indicate a concentratiön of 40 kU/l.
Serum samples
Serum samples (n = 184) were evaluated for CA 19-9 (pancreatic
cancer 40; pancreatitis 22; gastrointestinal tumours 70; alcoholic
liver cirrhosis 11; several forms of hepatitis 20; sera of blood do-
nors 21), and 188 serum samples for CA 125 (ovarian cancer 75;
pancreatic cancer 40; hepatocellular carcinoma 18; alcoholic liver
cirrhosis 11; several forms of hepatitis 24; sera of blood donors 20).
Serum samples were stored not longer than 4 weeks at -20 °C
until analysis. Sera thawed once or twice were used in nearly all
determmations. Stability of the antigens was tested by repeated
analysis of selected samples after a storage period of 2 months.
Statistics
Coirelations were generally tested by non-parametric methods
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This correlation varied when the results were subdivided
according to the diagnosis. For CA 19-9, the coefficients
of correlation were higher than the overall correlation
in pancreatic carcinoma (r = 0.96), and were equal in
gastrointestinal cancer (r - 0.88). The concordance of
the concentrations in serum was lower in patients with
hepatitis (r = 0.82), liver cirrhosis (r = 0.80), and pan-
creatitis (0.78), and differed substantially in normal sub-
jects (r = 0.47). For CA 125, a correlation significantly
below the overall value was observed in healthy individ-
uals only (r = 0.56).
The detection limits of the assays (calculated äs the low-
est value distinguishable from the zero calibrator + 3
S. D.) were 1 .5 kU/1 for both ILMAs, and 2 kU/1 for CA
19-9 IRMA and 3 kU/1 for CA 125 IRMA.
Tab. 3 Precision profile of CA 19-9 IRMA, CA 19-9 ILMA, CA
125 IRMA, and CA 125 ILMA (data calculated from serum
samples from patients).
>
Concentrations
rirTT/nLKU/IJ
11
21
31
51
71
101
251
- 10
- 20
- 30
- 50
- 70
- 100
- 250
-1000
Coefficient of Variation [%]
CA 19-9
IRMA
12.4
4.3
3.1
3.3
3.3
3.4
4.5
4.1
ILMA
12.7
6.8
3.6
4.0
4.3
3.4
3.7
4.3
CA 125
IRMA
94
4.8
3.5
4.0
2.5
4.9
5.0
3.4
ILMA
120
8.4
4.8
4.8
4.5
5.6
7.4
6.4
No data concerning the test specificity are reported,
since lipaemic or haemolytic sera were not included in
this evaluation.
j Quality control of CA 19-9
l
\ Intrarassay Variation
The intra-assay Variation was estimated from the repro-
ducibility of the examined controls (n = 8), äs well äs
from the mean coefficient of Variation of the patient
samples (tab. 2). An unacceptably high coefficient of
Variation was observed when assaying the Bioref control
with CA 19-9 ILMA (CV = 17%).
In serum samples, the reprpducibility of the IRMA and
the ILMA was nearly independent of the antigen level
at concentrations in the ränge 20-1000 kU/1 (tab. 3).
centration: + 1.3%, CV = 3.7%; n = 8), whereas lower
means were observed with the IRMA (internal control
low, mean deviation from target concentration: —3.6%,
CV = 6.2%; internal Standard high, mean deviation
from target concentration: -3.2%, CV = 6.3%; n = 8).
The linearity of the assays was checked by diluting
serum specimens of high antigen concentrations (coef-
ficient of correlation > 0.98 in both assays).
Inter-assay Variation
To simulate the Situation in a routine laboratory, inter-
assay Variation was determined by using five different
lots (tab. 4).
Accuracy andprecision ofthe internal control samples Tab. 4 Accuracy and precision of the CA 19-9 controls (n = 8).
When evahiated in the respective assay, the internal con-
trols from the manufacturer were slightly higher than
indicated in the ILMA (mean deviation from target con-
Tab. 2 Intra-assay Variation of CA 19-9 using different control
specimens (n = 8).
ILMA-control
Lyphocheck level 1
Lyphocheck level 2
Bioref
IRMA-control low
IRMA-control high
Serum samples
IRMA
CA 19-9
[kU/1]
—
23.2
122
48
56.7
113
CV
[%)
n.e.
6.3
5.7
4.7
2.5
4.8
5.8
ILMA
CA 19-9
[kU/1}
77.5
40.1
73.9
29.9
75.8
-
CV
[%]
7.7
6.2
7.3
17
11
n.e.
6.5
n. e. = not evaluated
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Control
ILMA
Lyphpcheck level 1
Lyphocheck level 2
Bioref
IRMA Control low
IRMA Control high
IRMA
Lyphocheck level 1
Lyphocheck level 2
Bioref
IRMA Control low
IRMA Control high
CA 19-9
Assigned
value
[kU/1]
n. k.
n. k.
40
47
84
17.1
85.5
40
47
84
Measured
value ± SD
[kU/1]
38.1 ± 6.0
69.6 ± 4.9
34.7 ± 6.2
56.7 ± 11.4
> 120
17.3 ± 3.4
91.5 ± 11.7
26.6 ± 3.7
45.3 ± 2.8
81.3 ± 5.1
CV
[%]
16
7.1
18
20
—
19
13
14
6.2
6.3
n. k. — not known
The controls from the IRMA were evaluated in the ILMA; they
were considerably higher than indicated for the IRMA, and the
Variation was greater.
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Lyphocheck conlrol specimens, analysed without refer-
ence values for CA 19-9 ILMA, showed a lot-to-lot re-
producibility of < 20% (n = 8) with variations similar
to those found for the IRMA (CV < 19%; n = 8). For
the Bioref sample, reference ranges below the concen-
tration of 40 kU/1 stated by the manufacturer were estab-
lished (ILMA: 34.7 ± 6.2 kU/1; IRMA: 26.6 ± 3.7
kU/1; n = 8).
Qual i ty control of CA 125
Intra-assay Variation
The intra-assay Variation was estimated from the repro-
ducibility of the duplicates from patient samples äs well
äs from the controls (tab. 5; n = 8) and was found to be
generally < 8% with one exception for each assay.
As for CA 19-9, the concentrations of CA 125 in serum
were subdivided into ranges to analyse the precision
profile (tab.' 3). The reproducibility of CA 125 IRMA
and CA 125 ILMA was found to be nearly independent
of the serum levels at concentrations between 20 and
1000 kU/1 (tab. 3).
Accuracy and precision ofthe internal control samples
The internal controls from the manufacturer evaluated
in the respective assay were 2.3% below the target value
in the ILMA (CV = 9.6%; n = 8) and 2.8% higher in
the IRMA (CV = 7%, IRMA control low). The high
IRMA control matched perfectly the target value of 110
kU/1 (CV = 5.3%).
The linearity of both assays was checked by diluting
serum specimens of high antigen concentrations (coef-
ficient of correlation > 0.99 in both assays).
Tab. 5 Intra-assay Variation of CA 125 using different
specimens (n = 8).
control
IRMA ILMA
CA 125 CV CA 125 CV
[kU/1] [%] [kU/i] [%]
ILMA Control
Lyphocheck level 1
Lyphocheck level 2
Bioref
IRMA Control low
IRMA Control high
Serum samples
_
30.0
185
19.5
51.8
114
—
n.e.
6.0
6.7
12.2
4.9
4.5
5.2
114
40.8
74.2
36.9
59.8
121
7.0
12
5.6
7.8
7.0
4.8
7.2
Tab. 6 Accuracy and precision of the CA 125 controls (n = 8).
Control CA 125
Assigned Measured
value value ± SD
[kU/1] [kU/1]
CV
ILMA
Lyphocheck level 1
Lyphocheck level 2
Bioref
IRMA Control low
IRMA Control high
IRMA
Lyphocheck level 1
Lyphocheck level 2
Bioref
IRMA Control low
IRMA Control high
46.8
91.1
50
53
110
28.5
154
50
53
110
• \
38.5 ± 4.6
66.7 ± 7.0
34.2 ± 3.5
54.0 ± 7.0
107 ±18.7
32.1 ± 3.0
187 ±20.4
26.5 ± 4.6
54.4 ± 3.8
110 ± 5.8
12
11
10
13
17
9.4
11
17
7.0
5.3
n. e. = not evaluated
Inter-assay Variation
As for CA 19-9, the investigation was performed with
five different kit lots (tab. 6).
Problems were encountered with regärd to the accuracy
of the Lyphocheck controls, äs none of the assays
matched the target concentrations, whereäs the inter-äs-
say reproducibility was acceptable in both assays (CV
< 17%, n = 8). CA 125 ILMA performed well with the
Bioref control (CV = 10%).
Discussion
We report a comparison of two immunoluminometric
assays for CA 19-9 and CA 125 with the established
immunoradiometric assays, in which we detennined
more than 180 serum samples under routine laboratory
conditions. We used five different lots for the determi-
nation of the concentrations of CA 125 and CA 19-9
in serum. Therefore, the inter-assay Variation not only
includes the between-assay precision of the laboratory,
but also the manufacturer's ability to produce tests with
high reproducibility.
These data are subject to the limitation that only.8
experiments were performed for the calculation of the
quality control. Twenty evaluations would be preferable,
but this number was not possible for financial and tech-
nical reasons.
In 1990, an evaluation of the chemiluminescence
immunoassays CA 15-3, CA 125 and,CA 19-9 (13) re-
ported a CV = 5-8% (inträ-assäy precision) and ä CV
= 5-17% (inter-assay precision). This study focused on
the precision and accuracy of reference samples and f e-
ported only a few results concerning serum samples
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from patients. The study by Plebani and co-workers (14)
reported an excellent inter-assay Variation of the new
method. The correlation in their collective was slightly
better for CA 125 (r = 0.99) than for CA 19-9
(r = 0.97), but they used parametric test methods for the
statistical evaluation.
Other studies investigated the diagnostic value of CA
125 by comparing enzyme-immunoassays with radio-
immunoassays, including more than 100 serum samples
(15, 16). In all cases, the coefficient of correlation was
better than r = 0.85, but the slope was found to differ
considerably from l for the EIA from Abbott relative to
the IRMA from Centocor (slope = 0.75 in the study of
Pittaway, (17)) with consequences for the sensitivity of
the enzyme-immunoassay, äs well äs for the conversion
of the tumour marker concentrations from one System to
another. Therefore, the long term Interpretation requires
concordant results in different assays. With some excep-
tions for the low serum concentrations (values < 30
kU/1), we obtained comparable results with both assay
Systems.
The fitting of the Standard curve with a spline function
after log/logit transformation excludes the zero cali-
brator of the Standard curve. Using the next calibrator
äs the lowest evaluable antigen concentration is prob-
lematic, in that lower concentrations cannot be reported
äs the authentic value. In the clinical use of tumour mar-
kers this is generally not a problem, but could become
a statistical one. In correlation analyses, small deviations
in the lowest concentration ränge do certainly not falsify
sample calculations based on more than 180 samples,
but are misleading in the healthy sample (r = 0.47 and
0.56 for CA 19-9 and CA 125, respectively).
The aim of the study was to compare the performance
of the assays and particularly the concordance of the
serum concentrations. Thus, we did a cross sectional
investigation in order to evaluate the maximal nümber
of serum specimens instead of a serial follow-up study
dealing repeatedly with the same serum matrix. The
concordance of the serum concentrations was in contra-
diction to some results obtained with the external con-
trols. While the internal controls were correct in all as-
says, problems were encountered in evaluating the accu-
racy (äs far äs this is possible in the absence of reference
method values) of the control sera from Bioref and Ly-
phocheck.
When this study started, no target values were indicated
for Lyphocheck control sera in the CA 19-9 ILMA. It
was therefore possible to determine only the inter-assay
Variation, which was acceptable at a value of 40 kU/1
and good at a value of 70 kU/1, considering that five
different lots were used for the ILMA. Some problems
arise from the poor chemical definition of the controls;
this concerns the structure of the antigens themselves,
äs well äs the poorly defined serum matrix. The Bioref
control sample is a pooled serum matrix, but can be used
only after establishing appropriate reference intervals
after a large nümber of runs. Considerable deviations
from the target concentrations were observed in our
study. A priority in the field of human tumour markers
remains therefore the production of standardised control
sera. This would allow the critical examination of small
deviations from the target values, in order to evaluate
the inter-assay Variation äs well äs the lot-to-lot Vari-
ation correctly.
The handling of the assays was nearly identical. A dif-
ference inherent in the luminescence assay is that the
isoluminol molecule bound to the antibody is consumed
during the chemiluminescence reaction rendering re-
peated measurements impossible.
We conclude that the immunoluminometric assay for
CA 125 and CA 19-9 with additional quality control
from the manufacturer could be an alternative to the im-
munoradiometric assay, because the serum values corre-
late well. At the moment, the performance of the radio-
immunoassays is better.
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